On Friday, CRISPR Therapeutics AG (NASDAQ: CRSP) opened lower -3.56% from the last session, before settling in for the closing price of $62.91. Price fluctuations for CRSP have ranged from $37.55 to $91.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 33402.13%. Company’s average yearly earnings per share was noted -203.12% at the time writing. With a float of $80.46 million, this company’s outstanding shares have now reached $84.88 million.
The extent of productivity of a business whose workforce counts for 407 workers is very important to gauge.
CRISPR Therapeutics AG (CRSP) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CRISPR Therapeutics AG is 5.21%, while institutional ownership is 66.18%. The most recent insider transaction that took place on Mar 15 ’24, was worth 1,449,628. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $72.48, taking the stock ownership to the 208,122 shares. Before that another transaction happened on Mar 15 ’24, when Company’s Chief Financial Officer sold 3,524 for $72.69, making the entire transaction worth $256,160. This insider now owns 6,476 shares in total.
CRISPR Therapeutics AG (CRSP) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 26.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -203.12% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Check out the current performance indicators for CRISPR Therapeutics AG (CRSP). In the past quarter, the stock posted a quick ratio of 17.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.97, a number that is poised to hit -2.00 in the next quarter and is forecasted to reach -4.08 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
The latest stats from [CRISPR Therapeutics AG, CRSP] show that its last 5-days average volume of 1.25 million was inferior to 1.87 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 17.59%. Additionally, its Average True Range was 2.95.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 15.21%, which indicates a significant increase from 3.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.71% in the past 14 days, which was lower than the 61.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $73.59, while its 200-day Moving Average is $59.57. Now, the first resistance to watch is $61.93. This is followed by the second major resistance level at $63.19. The third major resistance level sits at $64.03. If the price goes on to break the first support level at $59.83, it is likely to go to the next support level at $58.99. The third support level lies at $57.73 if the price breaches the second support level.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
There are currently 84,883K shares outstanding in the company with a market cap of 5.15 billion. Presently, the company’s annual sales total 371,210 K according to its annual income of -153,610 K. Last quarter, the company’s sales amounted to 201,210 K and its income totaled 89,350 K.
